Targeted Medication for Hypertrophic Cardiomyopathy: A first-in-class medication specifically targets heart muscle to reduce abnormal contractions caused by genetic variants that put the heart into overdrive.
For decades, clinicians have only been able to treat patients’ hypertrophic cardiomyopathy (HCM) symptoms – using drugs developed to treat other heart conditions – with limited effectiveness. Currently, non-specific medications are prescribed to treat some of the symptoms that HCM shares with other cardiovascular diseases. These therapies include beta-blockers, anti-arrhythmic drugs, calcium channel blockers and anticoagulants. A new treatment, however, works to reduce the root cause of the problem in many patients. A first-in-class medication specifically targets heart muscle to reduce abnormal contractions caused by genetic variants that put the heart into overdrive. By acting specifically on this mechanism in HCM patients, this novel treatment not only improves symptoms and quality of life, but potentially could slow progression of the disease. The FDA has assigned a target action date for this therapy of April 28, 2022. If approved, this would be the first medication explicitly dedicated to treating HCM and providing new hope to patients and physicians.
Latest from Today's Medical Developments
- Building, maintaining the Navy’s next generation of maritime platforms
- Pioneering battery-free cardiac implants
- KBC Tools & Machinery marks its 60th anniversary, Founder’s Day
- Address the challenges of machining high-temperature aerospace components
- Elevate your manufacturing operations with April’s Manufacturing Lunch + Learn
- AdvaMed statement on tariff announcement
- Collets – Not all are created equal
- ENGEL expands production capacities in the Americas; new plant opened in Mexico
